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Abstract
Trophoblast cells of the human placenta proliferate, migrate, and invade the pregnant uterus and
its vasculature in order to nourish the developing fetus, in a way that is imitated by malignant
tumors. Many similarities exist between embryo implantation and the growth of cancer cells. We
begin this article by reviewing decades of studies that have helped unearth the mechanisms that
contribute to the tumor-like phenotype of human trophoblast cells. Interestingly, these attributes
are only transient in nature, with stringent spatial and temporal confines. The importance of
intrinsic molecular controls that effectively circumscribe the extent and duration of trophoblast
incursion, becomes increasingly evident in abnormal pregnancies that are characterized by aberrant
trophoblast proliferation/invasion. We summarize and discuss the significance of abnormalities in
these regulatory mechanisms, and finally, speculate about the use of human trophoblastic cells as
model systems for the study of a variety of cellular processes. While on one hand, human placental
cells are bestowed with a capacity to proliferate indefinitely and invade extensively, on the other,
these cells are also replete with mechanisms to regulate these tumor-like attributes and eventually
progress to a senescent apoptotic state. This is therefore, a 'well-behaved' tumor. The comparison
in the present review is between the invasive cytotrophoblastic cell type and the tumor cell type.
Introduction
Placental development is directed towards the establish-
ment of a continuous nutrient supply to the developing
fetus. This requires efficient access of maternal blood to a
transporting surface, the multinucleate syncytiotrophob-
last layer. This is made possible by the rapid proliferation
and ensuing invasion of mononuclear trophoblast cells
into the maternal uterus and remodeling of the spiral
arteries therein, in a manner not different from most
aggressive tumors. Many similarities exist between
embryo implantation and the growth of cancer cells. The
establishment of an invasive phenotype, in both these
instances, comprises a host of cellular processes that
include expression or repression of specific cell adhesion
molecules, elaboration of matrix-digesting enzymes,
expression of proto-oncogene products, activation of tel-
omerase, and the acquisition of a rich blood supply. Fur-
ther, both the developing conceptus, and the growing
tumor, elude the immune system.
Once the blastocyst adheres to the uterus, the fetal
cytotrophoblast cells rapidly penetrate the endometrium.
Soon thereafter, mononuclear cytotrophoblast cells and
multinuclear syncytiotrophoblast are found mingled with
maternal decidual cells throughout much of the placental
bed, a condition that persists during the remainder of the
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groups of cytotrophoblast cells migrate through the
decidua, invade the walls of the spiral arterioles, and
replace the endothelial lining (a process called endovascu-
lar invasion) as far as the myometrial segments of these
vessels (interstitial invasion) [1]. The net result is the for-
mation of the human hemochorial placenta, in which
blood from the maternal circulation constantly bathes the
fetal chorionic villi throughout pregnancy.
The key to understanding this invasive cascade is the cor-
relation between cellular elements of migration and inva-
sion that are used so successfully by cancer cells as they
grow and metastasize. Malignant cells overcome the
restriction provided by basal laminae and other barriers.
Metastatic tumor cells break their contacts within their tis-
sue of origin, make their way into the circulation, and set
up a nidus of growth in a foreign environment, distant
from their normal location. In the process of metastasiz-
ing, they invade adjoining tissue before spreading to dis-
tant sites through the circulation. The components that
appear most important to tumor cell migration and inva-
sion are extra-cellular matrix (ECM) molecules (such as
fibronectin, laminin, collagen), their receptors (such as
the integrins), and the enzymes that degrade this matrix
(such as matrix-metalloproteinases).
The tumor-like attributes of the human placenta
Components crucial to tumor cell migration and invasion 
are shared by human trophoblast
Involvement of the extra-cellular matrix (ECM)
The ECM is composed of a network of secreted proteins
and glycoproteins that forms the 'ground substance' seen
outside cells and yet play a vital role in cellular function.
It is not just an inert framework that supports or sur-
rounds cells. It binds many growth factors and hormones
and can either sequester these signals from the cells that
contact it, or conversely, present the hormonal signals to
these cells. Tumor cells manifest their invasive properties
at several points: to enter and escape the circulation, and
to penetrate into normal tissues.
Much like malignant tumor invasion of host tissue, tro-
phoblast invasion of the maternal uterus is a multi-step
process involving attachment of the trophoblast cells to
the components of the ECM, degradation of the ECM and
migration through the ECM [2]. Collagen type I, the
major component of the interstitium ECM, has a remark-
able stimulatory effect on gelatinase secretion by cytotro-
phoblast [3]. Studies have clearly shown that the ECM
affects cell behavior [4]. Cytotrophoblast plated on
Matrigel respond differently depending on the thickness
of the Matrigel on which they are resting [4]. The mecha-
nisms underlying these altered responses are, however,
not clear.
Role of proteases
A plethora of studies suggest that trophoblast invasion is
not due to passive growth pressure, but due to an active
biochemical process. A cell is considered to be invasive by
virtue of its ability to secrete proteases capable of digesting
its immediate environment, and human cytotrophoblast
cells are no exceptions [2,5-7]. Serine proteases, cathep-
sins and matrix-metalloproteinases (MMPs) have all been
implicated in this process [8]. This secretion begins even
at the blastocyst stage [9].
MMPs are a family of zinc-dependent endopeptidases
[8,10]. They enzymatically digest ECM proteins and there-
fore play an important role in tissue remodeling processes
[3]. Regulation of enzyme activity can occur via differen-
tial activation of the MMP, or by tissue inhibitors of met-
alloproteinases (TIMP). Direct evidence links the
expression of MMPs, and particularly MMP-9, to the met-
astatic phenotype [7,11], and the tissue inhibitor of met-
alloproteinases (TIMP) to the inhibition of
metastatization [12]. Early studies [13] demonstrated that
a proteinase cascade is required for the invasion of
melanoma cells, and that the metalloproteinases play a
major role in this process. Further, an inverse correlation
is reported between TIMP levels and the invasive potential
of murine and human cells [14].
In vitro, human cytotrophoblast invades acellular, amni-
otic membranes [15] as well as reconstituted basement
Matrigel membranes [4,16]. This invasiveness was also
found to be independent of the surrounding uterine
microenvironment [15]. They thus inherently behave like
metastatic cells. This invasive behavior is clearly due to the
ability of cytotrophoblast to secrete MMPs, since TIMP
expression inhibits their invasiveness [17]. Furthermore,
cultured cytotrophoblast cells secrete MMPs and the
expression of MMP-2 and MMP-9 has been shown to
mediate cytotrophoblast invasion into the Matrigel [2,5].
Accordingly, changes in the synthesis of MMP-9 correlate
with gestation-related changes in trophoblast behavior.
Cytotrophoblast production and activation of MMP-9
peak during the first-trimester of pregnancy, coinciding
with maximal invasive behavior in vivo [17,18].
Transformed cells also often secrete a protease called plas-
minogen activator (PA), which cleaves a peptide bond in
the serum protein plasminogen, converting it into the
protease plasmin. Thus, the secretion of a small amount
of plasminogen activator causes a large increase in pro-
tease concentration by catalytically activating the abun-
dant plasminogen in normal serum. Normal cells treated
with protease exhibit some characteristics of transforma-
tion (loss of actin microfilaments, growth stimulation
etc.), suggesting that plasminogen activator secretion may
help maintain the transformed state of certain cell linesPage 2 of 12
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because the resulting increase in plasmin may help the
cells penetrate the basal lamina.
Interestingly, the normally invasive extra-embryonic cells
of the conceptus secrete PA while implanting in the uter-
ine wall; this provides a compelling analogy to invasion
by tumor cells. Human trophoblast cells also express
urokinase-type PA receptor [19], which can bind active
urokinase-type PA and localize proteolysis to the leading
edge of migrating cells [20].
Proteolysis of the thrombin receptor, protease-activated
receptor-1 (PAR-1), is known to enhance normal and
pathological cellular invasion [21]. Recent evidence sug-
gests that PAR-1 is the predominant thrombin receptor on
invasive human extravillous trophoblast cells [21], and
that PAR-1 (and potentially PAR-2 and PAR-3) may play
an important role in the invasive phase of human placen-
tation [21]. Receptor activation was shown to mediate
extravillous trophoblast invasion in vitro.
Integrins
ECM components are known to influence adhesion,
spreading and migration of cells through specific cell-sur-
face receptors called integrins [22]. Integrins are a large
class of hetero-dimeric transmembrane glycoproteins
composed of α- and β-subunits, and the ligand-binding
site is composed of parts of both chains. Depending on
the type of α/β combination, the integrins bind to differ-
ent matrix glycoproteins and mediate different cell-cell
interactions. For instance, α5β1 binds to fibronectin (Fn),
α6β1 binds to laminin, α1β1 binds to collagen type IV etc.
Tumor cells are known to produce elevated levels of these
receptors for the basal lamina proteins, along with
increased production of MMPs [10].
Interestingly, cytotrophoblast cells also have integrins,
which allow these cells to recognize their immediate envi-
ronment and adapt to it. Villous cytotrophoblast cells
(that are destined to eventually differentiate by fusion to
form syncytiotrophoblast) predominantly express the
α6β4 integrin (a probable laminin receptor [7]), polar-
ized along the basement membrane. In contrast, the
highly invasive extra-villous cytotrophoblast cells (that
break through the syncytial masses as multi-layered col-
umns, to reach the decidua, the intima of the uterine
blood vessels and the proximal-third of the myometrium)
modulate the expression of their integrins. In the proxi-
mal region (the cytotrophoblast-columns), they express
α6β4 in a non-polarized way, whereas in the most distal
part (the placental bed), they express the α5β1 integrin, a
Fn receptor []. Thus, as cytotrophoblast cells migrate from
the villi into the decidua, they modulate their integrin rep-
ertoire from being α6β4-positive/α5β1-negative to
becoming α6β4-negative/α5β1-positive. Endovascular
cytotrophoblast cells express yet another integrin, α1β1, a
collagen receptor [23] along with vascular cell adhesion
molecule (VCAM) [10]. These changes in expression of
specific cell adhesion molecules, are linked to the acquisi-
tion of an invasive phenotype, as the shift now allows the
aggressive trophoblast cells to blend in with the endothe-
lial cells as penetration of maternal vessels progresses
[24]. Likewise, the wide range of altered behaviors that
underlie malignancy are believed to have their basis in
new or variant surface proteins made by malignant tumor
cells.
Molecules made by the surrounding parenchyma, in some
cases, are known to influence the potential of either can-
cer cells or trophoblast cells to invade. For instance, Insu-
lin-like Growth Factor Binding Protein-1 (IGFBP-1),
which is the major secretory product of the decidualized
endometrium, has been shown to bind to the α5β1
integrin and stimulate cellular migration [25]. As this
integrin is upregulated by the invading trophoblast [23],
and is also present along with αvβ3 in metastatic malig-
nant melanoma cells [26], such a mechanism may serve to
activate integrins and promote invasive behavior during
placental development. In vitro studies using human pla-
cental cells, also seem to suggest this. Both IGF-II (which
is produced by the invasive extra-villous trophoblast cells
throughout gestation) and IGFBP-1, were found to syner-
gistically stimulate the invasive properties of first-trimes-
ter trophoblast cells [27].
Telomerase expression and trophoblast proliferation
The success of tumor progression is dependent on the
ability of tumor cells to proliferate indefinitely. Normal
human somatic cells have a defined proliferative capacity.
In contrast, tumor cells have an infinite life span and con-
tinue to divide until their host dies. Recent progress in
research in cellular ageing has revealed that telomeres, or
distal ends of chromosomes, play essential roles in this
process [28].
Role of telomerase in cellular immortality
Telomeres are complex DNA-protein structures that grant
stability to chromosomes by effectively shielding against
exonuclease digestion and preventing aberrant recombi-
nation [28]. Telomere shortening (owing to the 'end-rep-
lication problem') [29] has been proposed as a regulatory
mechanism that controls the number of times a cell can
divide before undergoing cellular senescence [30-32].
Immortal cancer cells escape this growth-arrest signal by
activating a cellular mechanism of telomere length main-
tenance [30]. Most often, this mechanism involves the
activity of an enzyme called telomerase.Page 3 of 12
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complex that helps to compensate for replication-associ-
ated loss in telomeric repeats, which are essential for chro-
mosome stability in actively dividing cells [33,34].
Telomerase activity has been detected in most human
tumor cells and tissues examined to date, as well as in
human germ-line tissues, but as a sharp contrast, not in
most normal somatic cells, thereby linking telomerase to
unlimited cell proliferation and hence cell immortality
[34]. Studies over the last several years have indicated the
obligate requirement of telomerase for progression of
human cancers [30,35]. This is needed to achieve expo-
nential growth patterns that would be otherwise unattain-
able.
Trophoblast telomerase activity
In contrast to the majority of human somatic tissues and
alike most progressive cancers, the human placenta
expresses telomerase activity [36,37]. Further, our studies
suggest a functional role for telomerase in the mainte-
nance of normal pregnancy [36].
We observed that mononuclear human cytotrophoblast
cells retain their proliferative potential throughout gesta-
tion [36]. This observation has a very special significance.
The presence of functional telomerase in human cytotro-
phoblast cells (and its retention even at term) probably
ensures a capacity for high rates of proliferation, an event
that is absolutely essential for normal placental growth
and function.
The developing human fetus is a semi-allograft to the
mother. While half the antigens of the fetus, being mater-
nally derived, would be considered 'self', the other half,
being paternally derived, would be considered 'foreign'.
Therefore, one would expect that the mother would
mount an immune response against the fetus. Yet, such an
immune response leading to the death of the fetus is not
usually seen. Although the placental association places
the fetal circulation in close proximity with the maternal
circulation, these two blood-streams do not mix. They are
separated by tissue layers called the placental barrier. In
humans, the placental barrier is essentially composed of
the multinucleate syncytiotrophoblast layer alone. The
outer surface of the syncytiotrophoblast layer is continu-
ously bathed in maternal blood throughout gestation.
Early in pregnancy, the fetal capillaries lie in a central
position in the villus, but as pregnancy advances, the thin-
walled anastomosing, endothelial fetal capillary tubes
become more pronounced, come in close apposition with
the inner surface of the syncytiotrophoblast layer and dis-
perse the cytotrophoblast cells so that, the syncytiotro-
phoblast layer becomes the only barrier that effectively
separates fetal and maternal circulations. Hence, the inte-
gral maintenance of this layer throughout gestation is of
prime importance. The syncytiotrophoblast layer, how-
ever, is not immortal. It is well known that human syncy-
tiotrophoblast has a defined life span, and is programmed
to die at the end of it. Accumulated evidence points to a
role for apoptosis in this renewal process. And therefore,
there is the need for a mechanism to constantly replenish
this crucial layer that periodically disappears.
Our studies prove the existence of mechanisms (namely,
the continued presence of telomerase activity even in cells
of term placenta) to aid in the maintenance of this vital
layer [36]. Cytotrophoblastic stem cells are capable of
division throughout gestation, while a subset of post-
mitotic cells serves to replenish an outer syncytiotrophob-
last layer after membrane fusion.
The human placenta and immune privilege
Another recognized property of malignant cells is their
ability to elude the immune system. The differential rec-
ognition between 'self' and 'non-self' provides the basis
from which most immunological reactions proceed.
Tumor cells may cover up antigens that would otherwise
mark them for destruction, or they may rid themselves of
cell-surface proteins that lymphocytes use to recognize
foreign cells (major histocompatibility complex antigens
or MHCs).
In humans, embryos are internalized. Although this is a
biological adaptation that provides protection against
environmental hazards, this arrangement also creates a
seemingly threatening situation. The intimate juxtaposi-
tion of fetal and maternal cells should allow ample oppor-
tunity for the development of maternal immune
responses against the fetal semi-allograft that also
expresses paternally derived antigens, which are foreign to
the mother. Yet, despite genetic differences, mothers do
not reject their semi-allogeneic embryos. Many hypothe-
ses have been advanced to explain the immunologically
privileged status of the feto-placental unit. These
inclclude:
Immunosuppressive environmental conditions [38]
The trophoblastic epithelium of the placenta maintains a
high concentration of steroid and protein hormones that
are believed to confer immuno-protection to the growing
fetus. The increased levels of progesterone at the placen-
tal/decidual border are equivalent to the in vitro levels,
which inhibit lymphocyte responses to mitogens or allo-
geneic cells. This hormone may thus play a significant role
in blunting maternal immune responses against the fetus
[39]. Similarly, the activity of lymphocytes can be sup-
pressed in vitro by a variety of substances synthesized in
the course of a normal pregnancy including, human Cho-
rionic Gonadotropin (hCG), human Placental Lactogen
(hPL) [or human Chorionic SomatomammotropinPage 4 of 12
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proteins and glycoproteins [40,41]. The uterus also pro-
duces high concentrations of Transforming Growth Factor
(TGF β) and prostaglandin E2 (PGE2), both of which are
potent inhibitors of immune responses [42,43]. Placental
production of anti-inflammatory cytokines, TGF β2, Inter-
leukin (IL)-4 and IL-10 have been postulated to counter-
act the deleterious effects of inflammatory cytokines IL-2,
Interferon (IFN)-γ and Tumor Necrosis Factor (TNF)-α
[44,45]. Furthermore, Interferon β produced by the
human trophoblast, is reported to have marked immuno-
suppressive effects on the mitogen-induced proliferation
of human T-cells and B-cells in vitro in a dose-dependent
manner, suggesting that the local cytokine network at the
feto-maternal junction may also play an important role in
the immunobiology of human pregnancies. Interestingly,
trophoblast cells also abundantly express Fas-L (or CD95-
L). Fas-L expression has been proposed to contribute to
immune privilege in this unique environment, by foster-
ing apoptosis of activated Fas-expressing lymphocytes of
maternal origin [46]. An apoptotic process mediated by
Fas-L may thus play a role in placental invasion during
implantation, and this underscores similarities between
trophoblast cells and neoplastic cells. Recent evidence
suggests that hCG may be a crucial link in the develop-
ment of peritrophoblastic maternal immune tolerance
and may facilitate trophoblast invasion by regulating the
Fas-FasL system [47].
Expression of regulatory proteins that interfere with the complement 
cascade [48]
Expression of the 'decay-accelerating factor' (or DAF) has
been reported on the trophoblastic epithelium of the feto-
maternal interface [49]. It was also observed that there
was a quantitative increase in the expression of DAF dur-
ing placental development [49]. Therefore, it was sug-
gested that DAF might function by specifically inhibiting
amplification convertases formed at the interface, either
directly or indirectly, as a result of maternal complement
activation [49]. More recently, the roles of two more pro-
teins, 'membrane co-factor protein' (or MCP), which acts
at the level of the C3 convertase enzymes to activate C3 to
C3b, and another protein 'CD59', which regulates the for-
mation and function of the terminal cytolytic membrane
attack complex (MAC), have been implicated in the regu-
lation of complement activity [50].
The provision of an immunologically inert barrier between maternal 
and fetal cells [51]
The strategically positioned cells of the placenta (or the
trophoblast cells) completely encase the developing
embryo and thereby prevent circulating maternal immune
cells from recognizing foreign fetal antigens. Further, tro-
phoblast cells themselves regulate the expression of their
MHCs (the products of which are central to immune rec-
ognition and subsequent rejection of grafts) in a unique
fashion. Unlike all other nucleated cells, trophoblast cells
lack constitutive expression of the highly polymorphic
Class I genes [41,52-54]. Instead they express a non-poly-
morphic gene, HLA-G, in abundant measures. The expres-
sion of this non-classical MHC class I gene on the
cytotrophoblast surface, together with the total lack of
expression of HLA heavy chain genes on syncytiotrophob-
last, suggested that the non-polymorphic nature of HLA-
G was responsible for the lack of cytotoxic immune
responses in the placenta [41,52-54]. Interestingly, IFN β
has been shown to enhance both transcription and cell
surface expression of HLA-G on human trophoblast cells
and amniotic cells [55].
In addition to the lack of constitutive expression of poly-
morphic MHC Class I genes, trophoblast cells also lack
interferon γ-inducible expression of MHC Class I or II
genes, suggesting that there is an active repression of
cytokine-induced expression of Class I and Class II genes
as well, in trophoblast cells [41,43,52,53]. Major candi-
dates for potent suppressors of MHC gene expression in
human trophoblast cells include hCS, and a novel
untranslated RNA or 'utron', called Trophoblast STAT
Utron [41].
However, no single hypothesis has been able to convinc-
ingly explain the successful survival of the 'transplanted
semi-allograft' throughout pregnancy. It is possible that
many (or all) of these proposed mechanisms work in con-
cert. In any case, acquisition of this 'transient state of tol-
erance' specific for paternal alloantigens suggests, that
immune privilege at the feto-maternal interface is
expressed systematically, is actively acquired and is neces-
sary for survival of the fetus to term. This situation is rem-
iniscent of that seen in most tumors. As with trophoblast
cells, tumor cells often have low levels of Class I HLA, and
in some instances even lack a full complement of the anti-
gens [56].
Trophoblast 'Pseudo-vasculogenesis'
Acquisition of extensive vascularization
Another common feature of placentation and cancer
metastasis is the acquisition of extensive vascularization.
Both the implanting embryo and the newly arrived tumor
nodule require a rich blood supply in order to grow. Ang-
iogenesis is the process of growth and development of
new capillary blood vessels from pre-existing vessels.
When pathological, it contributes to the development of
numerous types of tumors, and the formation of metas-
tases. In order to grow, carcinoma need new blood vessels
to form, so that they can constantly feed themselves.
Therefore, the concept according to which the develop-
ment of cancer is angiogenesis-dependent, is well recog-
nized. The transition from the latent phase to the invasivePage 5 of 12
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the angiogenic-switch. It implies complex cellular and
molecular interactions between cancerous cells, endothe-
lial cells and the components of the ECM. This is made
possible by specific proteins secreted by tumor cells that
are able to stimulate the proliferation of capillary
endothelial cells. The molecular communication that
sends signals to a vessel to sprout and branch through the
ECM in a tumor, is remarkably similar to the processes
that occur during embryo implantation and placentation
[10]. As described earlier, human cytotrophoblast cells
and invasive melanoma both exhibit similar patterns of
integrin expression that have been shown to adopt a vas-
cular phenotype capable of invading maternal spiral arte-
rioles, strikingly similar to those noted in endothelial cells
as they migrate toward the tumor [57,58]. During angio-
genesis, endothelial cells also exhibit invasive and migra-
tory behavior and utilize cell processes similar to those of
both invading cytotrophoblast cells and spreading tumor
cells [10].
Involvement of Fibroblast Growth Factor (FGF), Vascular Endothelial 
Growth Factor (VEGF)
There is evidence that human trophoblast cells release
cytokines including basic Fibroblast Growth Factor
(bFGF) [59]. During tumor growth, angiogenesis can be
initiated by bFGF or by Vascular Endothelial Growth Fac-
tor (VEGF), which signal nearby vessels to send out new
branches [60]. VEGF and bFGF are both very potent initi-
ators of angiogenesis. During embryo implantation, VEGF
mRNA and protein are localized in endometrial macro-
phages, as well as in the stroma and glandular epithelium
[61,62]. Interestingly, invading human cytotrophoblast
cells express the VEGF receptor [63]. Once angiogenesis is
initiated, events at the apex of a branching vessel are sim-
ilar to those in other invading cells. Integrin-mediated
migration and MMP activity directed toward the leading
edge, create a path through the ECM.
Oncogenes and the human placenta
The similarity between trophoblastic cells and trans-
formed cells impelled several investigators to study the
expression of oncogenes in the human placenta. Onco-
genes are altered versions of pre-existing genes (called
proto-oncogenes), whose products now cause inappropri-
ate cell growth leading to cancer. Proto-oncogene prod-
ucts include growth factors, growth factor receptors,
intracellular signal transducers, cell cycle control proteins,
nuclear transcription factors [24,64].
Transcription factors: Activator Protein-1 (AP1), c-Myc
The most widely known transcription factor, the AP-1
complex (Activator Protein-1), is a heterodimer of Jun and
Fos, products of the proto-oncogenes c-jun and c-fos,
which belong to the family of immediate response genes.
There are numerous reports showing that AP-1 is involved
in the MMP-1 response to IL-1 (Interleukin-1), TNF
(Tumor Necrosis Factor) and TGF β [7,24]. AP-1 is also
involved in the MMP-3 regulation by PDGF and TGF β
[7,24]. MMP-1, -3 and most importantly, MMP-9, have a
promoter site capable of binding Fos-Jun heterodimers.
The AP-1 complex thus occupies a focal position in medi-
ating signals that lead to increased MMP expression, and
consequently, to the acquisition of an invasive pheno-
type.
Fos and Jun are both abundantly expressed in the early
human trophoblastic cells [65]. Interestingly, the levels of
c-fos expression in human amniotic and chorionic cells
are close to the level of v-fos expression that results in the
induction of osteosarcoma in mice and transformation of
fibroblasts in vitro [66]. Further, EGF (Epidermal Growth
Factor)-mediated effects on human trophoblast prolifera-
tion/ differentiation are believed to be via modulation in
c-fos and c-jun expression [67]. Jun B, a member of AP-1
transcription factor family, has been shown to be essential
for establishment of proper vascular connections with the
maternal circulation during mammalian placentation
[68]. Lack of Jun B resulted in embryonic lethality.
Another proto-oncogene of interest is c-myc, whose prod-
uct is a transcription factor essential for cell cycle progres-
sion. Interestingly, several groups have shown that c-Myc
activates telomerase, an effect attributed to direct interac-
tion of c-Myc with the hTERT promoter [69,70]. Altera-
tion of c-myc expression is associated with a large number
of tumors of diverse origin, that are characterized by
uncontrolled telomerase activity. Similar to many actively
dividing cancer cells, c-Myc expression was found to be
critical for early trophoblast proliferation [71].
Growth factors: Platelet-derived growth factor (PDGF)
The proto-oncogene c-sis encodes the β chain of PDGF.
This cytokine is expressed by the early proliferative tro-
phoblast (both villous and extra-villous cytotrophoblast
cells) and by blastocysts [72-74]. The high transcriptional
level in cytotrophoblast cells is comparable to that in
human tumor cell lines that actively produce PDGF [72].
Further, the localization of c-sis transcripts in these cells,
parallels that of c-myc transcription. Since PDGF stimu-
lates the expression of c-Myc (which is a part of the post-
receptor intracellular signaling pathway for the stimula-
tion of cell proliferation by growth factors), and since
these two products are co-localized in cytotrophoblastic
cells, it is believed that PDGF at least partially controls tro-
phoblast proliferation [72].Page 6 of 12
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Macrophage-Colony Stimulating Factor receptor (M-CSF-R), VEGF-R
The human placenta also expresses c-erb B and c-fms, the
products of which are the EGF and the M-CSF (Macro-
phage-Colony Stimulating Factor) receptors, respectively.
EGF receptor (EGF-R): EGF-Rs are predominantly found
on villous cytotrophoblast cells and syncytiotrophoblast
[75,76]. Interestingly, the surrounding decidual cells also
massively express EGF-R [24], thereby implying impor-
tant functional roles for EGF-R ligands at the feto-mater-
nal interface. There are 3 known ligands for EGF-R: EGF,
TGF α and amphiregullin. All 3 ligands have been shown
to enhance extra-villous trophoblast proliferation [77].
Immunoreactive EGF has been localized to uterine epithe-
lial cells and decidual cells, as well as to both cyto- and
syncytiotrophoblast of the chorionic villi [78]. Immuno-
reactive TGF α has been detected in decidual cells and
nearly all trophoblast sub-populations of the human pla-
centa at various gestational ages [77]. Amphiregullin has
been demonstrated in the cytoplasm, as well as in the
nuclei of syncytiotrophoblast cells of only early gesta-
tional placentae (upto 18 weeks) [79]. EGF and TGF α
were found to stimulate normal cytotrophoblast prolifer-
ation acting through these high-affinity binding sites [80].
Studies have also shown that EGF acts as an autocrine fac-
tor in regulating early placental growth and function in
synergy with thyroid hormone [80]. The TGF α-EGFR
autocrine loop has been implicated in the uncontrolled
proliferation of malignant trophoblast cells [81].
M-CSF receptor (M-CSF-R): CSF-1 is a homodimeric glyco-
protein growth factor required for the proliferation and
differentiation of mononuclear phagocytic cells. It has
also been shown to have a role in placental growth and
development under hormonal influence [82]. During
pregnancy, the mRNA for its receptor has been localized
to the trophoblast by in situ hybridization [83]. M-CSF-Rs
[84,85] are already expressed at the blastocyst stage, then
later again by the invasive extra-villous cytotrophoblast
cells. CSF-1 significantly increases the proliferation of
first-trimester cytotrophoblast cells in an autocrine fash-
ion. The expression of M-CSF-R has been correlated with
trophoblastic invasiveness and the metastatic phenotype
[24].
VEGF receptor (VEGF-R): The product of the c-flt proto-
oncogene is an fms-like tyrosine kinase, which is the
receptor for VEGF. This VEGF receptor is expressed by the
invasive extra-villous cytotrophoblast cells [63]. As
described earlier, VEGF produced by the endometrium, is
a potent angiogenic factor and plays a crucial role during
embryo implantation in the vascularization process. The
expression of the functional receptor by the trophoblast
thus favors the invasion process. VEGF has also been
shown to promote proliferation of the invasive extra-vil-
lous cytotrophoblast cells [86]. The c-flt gene product
(VEGFR-1) can also be bound by the trophoblast-derived
Placenta Growth Factor (PlGF; a member of the VEGF
family of angiogenic factors) to affect cell proliferation,
invasion and/or other metabolic activities in an autocrine
manner [87].
Evidence for 'autocrine regulation' of trophoblast growth
The parallel production of growth factors as well as their
cognate receptors in the human placenta suggests an
'autocrine regulatory model' in which normal trophoblast
cells synthesize agents capable of promoting their own
proliferation. Autocrine regulation of growth is key to sev-
eral tumor systems and hence this finding is interesting in
the placental context.
A fundamental characteristic of transformed cells is that
they continue to divide even when their normal non-
malignant counter-parts cease dividing (loss of growth
control). Transformed cells often dispense with hormone-
or growth factor-requirement for their growth, and can
thrive in initial serum concentrations that are much lower
than those required by normal cells. Many transformed
cells continuously produce both growth factors and their
receptors, thereby providing themselves an auto-stimula-
tory growth impetus. Inappropriate or unregulated
expression of these growth stimulators results is a loss of
capacity for growth arrest.
Although the literature cited here is not meant to be
exhaustive, and although the exact mechanisms operative
in vivo are still not entirely certain, it is clear from the
aforementioned studies that human cytotrophoblast cells
are well equipped with the biochemical mediators neces-
sary for metastatic growth and invasion. This is absolutely
essential for successful implantation and subsequent pen-
etration of the endometrial stroma and blood vessels,
which in turn is indispensable for proper feto-maternal
exchange. The ability of the trophoblast cells to attach,
proliferate and invade thus provides a developmental
strategy that eventually allows for a mature placenta and a
viable fetus.
The transient nature of 'trophoblast 
tumorigenesis'
It is clear that trophoblast cells utilize the same molecular
mechanisms as those of tumors for their growth, as well as
for their migratory and invasive functions. The human
placenta can thus be regarded as a physiological counter-
part of highly invasive malignant tumors. However, the
comparison ends here, since the placenta knows precisely
when to stop growing. Although indispensable for normal
pregnancy, it is important to note that the tumor-likePage 7 of 12
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/15attributes of human trophoblast cells are only transient in
nature. This is therefore, a 'well-behaved' tumor.
The process of trophoblast penetration into the maternal
uterus peaks during the twelfth week of gestation but
declines very rapidly thereafter, suggesting that the highly
specialized invasive behavior of human placental cytotro-
phoblast cells is also one that is closely regulated, unlike
tumor invasion of host tissue. This 'regulation' that oper-
ates in these cells, limits invasion, both spatially and tem-
porally; spatially, to the first-third of the myometrium and
temporally, only till about the middle of gestation
[88,89]. Particularly striking is the precision with which
these controls function.
What sets the physiological process of placentation apart
from tumorigenesis is the 'controlled program of terminal
trophoblast differentiation'. 'Terminal differentiation'
describes a programmed event, generally resulting in
changes in gene expression and an irreversible exit from
the cell cycle. This functional differentiation process in
human cytotrophoblast cells allows for the synthesis and
secretion of a variety of proteins and hormones of preg-
nancy. This is also an important regulatory event that
checks the proliferative potential of these otherwise
tumor-like cells.
Our studies indicate that ordered differentiation in
human trophoblastic cells is integrally associated with a
terminal loss in telomerase activity [36]. Further, we also
identified TGF β1 as an important autocrine/paracrine
factor that serves to keep the proliferative potential of
these cells in tight check, through its ability to specifically
suppress hTERT (human Telomerase Reverse Tran-
scriptase, the catalytic subunit of the telomerase holo-
enzyme complex) gene expression, and thereby prevent
the onset of malignancy [36].
Clearly, the proliferative lifespan of human trophoblastic
cells is limited by intrinsic controls. Further, hormones
and growth factors maintain an added level of control
over the expression of active enzymes and other proteins
needed for cellular immortalization [36,90]. Our studies
revealed that TGF β1 is a major factor governing c-Myc
expression during human trophoblastic differentiation
[90]. A loss in c-Myc expression was accompanied in par-
allel, by a significant increase in the expression of Mad1, a
known repressor of hTERT transcription. We also
observed a simultaneous increase in the expression of cyc-
lin-dependent-kinase inhibitors, p21, p27, p15 and p16,
associated with a loss in expression of Cyclin A2 and Cyc-
lin E. Many of these events have been correlated with an
irreversible loss in telomerase activity, in various systems.
Thus, TGFβ1, while allowing differentiation, may simulta-
neously induce multiple signals that control trophoblast
proliferation on one hand by regulating the expression of
key components required for progression through the cell
cycle, and on the other, by controlling telomerase activity
[90]. Our studies also implicate functional roles for the
hormones, 17β-estradiol and Gonadotropin Releasing
Hormone, in the regulation of functional differentiation
in the human trophoblast (unpublished observations).
The human placenta, therefore, presents a unique contrast
to the unregulated proliferation seen in metastatic cancer.
Importance of intrinsic molecular controls: 
pregnancy-related disorders resulting due to 
aberrant trophoblast proliferation/invasion
The invasion of cytotrophoblast cells to a proper depth
and regulated proliferation of these cells, are major factors
in determining the outcome of pregnancy. Dysregulation
of this invasive behavior and/or controlled proliferation
of the placenta has been correlated with a wide spectrum
of abnormal pregnancies [91,92], many of which invaria-
bly result in maternal/fetal death.
Excessive invasion can lead to deficient development of
the decidua with abnormally firm attachment of the pla-
centa directly onto the myometrium (a condition called
placenta accreta), to the extension of the placenta into the
myometrium (placenta increta), or to invasion through
the myometrium to the uterine serosa and even into adja-
cent organs (placenta percreta) [92].
Gestational trophoblastic tumors
Uncontrolled trophoblast proliferation/growth often
results in Gestational Trophoblastic Disease (GTD). GTD
encompasses a diverse group of lesions. The pathological
conditions are variously termed as complete/partial hyda-
tidiform mole, invasive mole, choriocarcinoma, placental
site trophoblastic tumor, epithelioid trophoblastic tumor,
exaggerated placental site and placental site nodule
according to the modified WHO classification [89]. These
diseases arise due to discrete pathologic aberrations occur-
ring at different stages of trophoblastic differentiation.
Arrested differentiation often results in true neoplasms;
some other lesions represent abnormally formed placen-
tae with a pre-disposition for neoplastic transformation of
the trophoblast [93]. These tumors are often associated
with abnormal expression of cell cycle regulatory products
including cyclins, cyclin-dependent-kinases (cdks) and
tumor suppressors such as p53 [94].
Choriocarcinoma is the most severe form of GTD and is
characterized by distant metastatic spreads. The lungs are
the most common sites of metastasis. The trophoblast
cells that comprise the choriocarcinoma resemble the
primitive trophoblast of the pre-villous stage during pla-
cental development, arrested in specific stages of differen-
tiation [89].Page 8 of 12
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ized by enlarged, edematous chorionic villi accompanied
by a variable amount of proliferative trophoblast popula-
tion [89]. A complete mole is characterized by uncon-
trolled, circumferential proliferation of villous
trophoblast surrounding the abnormally enlarged villi. In
contrast, a partial mole has an intimate admixture of two
populations of villi: enlarged, edematous villi and nor-
mal-sized villi, which may be fibrotic. The most serious
complication after evacuation is persistent or metastatic
GTD and the risk of developing choriocarcinoma [95].
Invasive mole is a variant of complete hydatidiform mole
in which hydropic villi invade the myometrium or blood
vessels or, more rarely, are deported to extra-uterine sites
[89].
Placental site trophoblastic tumor is a relatively uncom-
mon form of GTD composed of neoplastic implantation
site intermediate trophoblastic cells. This tumor resem-
bles the trophoblastic infiltration of the endometrium
and myometrium of the placental site during early preg-
nancy. For the most part, this tumor is benign, but turns
aggressive in approximately 15% of the patients [96].
Epithelioid trophoblastic tumor is an unusual tumor dis-
tinct from the other GTDs, with features resembling a car-
cinoma. These tumors may not be responsive to the
chemotherapeutic agents used in the treatment of other
types of GTDs. Metastasis and death occurs in approxi-
mately 25% of patients [97].
Uncontrolled trophoblast proliferation and penetration
leads to unlimited growth of villous trees and results in an
extremely large but undifferentiated placenta, which is
functionally insufficient. This situation is typically associ-
ated with clinical features such as Rhesus incompatibility
or persisting villous immaturity in post-mature placentae
[98].
Pre-eclampsia
Inadequate trophoblast invasion, on the other hand, has
been implicated in the pathophysiology of pre-eclampsia,
which is the leading cause of maternal death in the indus-
trialized world and which increases the perinatal mortal-
ity by a factor of five [92]. Although the exact cause of pre-
eclampsia is unknown, the characteristic lesion is the
result of shallow interstitial invasion by cytotrophoblast
cells and, more consistently, limited endovascular inva-
sion. Importantly, the differentiation of the extra-villous
cytotrophoblast is perturbed to a very great extent [99].
Further, in this disorder, cytotrophoblast cells that invade
uterine vessels fail to switch their repertoire of adhesion
molecules to resemble that of vascular cells [57,58]. More-
over, these cells are deficient in the expression of MMP-9,
which has been shown to be crucial for human trophob-
last invasion, and in the expression of the receptor for
VEGF (VEGFR-1), which is a key regulator of angiogenesis
[100]. Thus, with compromised adhesive and degradative
properties of cytotrophoblast cells in this disorder, the
uterine arterioles remain small-bored, high-resistance ves-
sels that cannot adequately respond to the ever-increasing
fetal demands for blood flow. Recent evidence also impli-
cates a role for HLA-G in the prevention of pre-eclamptic
pregnancies [101]. A striking feature of pre-eclamptic
pregnancies is that expression of HLA-G protein is
reduced in term placentae compared with that in normal
pregnancy. Defective HLA-G function has been hypothe-
sized to contribute to the low trophoblast invasion and
vascular abnormalities observed in pre-eclamptic placen-
tae [101].
Intra-uterine growth retardation (IUGR) and missed 
abortion
Another related disorder is Intrauterine Growth Retarda-
tion (or IUGR), which is a significant cause of increased
infant mortality and morbidity, affecting upto 8% of all
pregnancies [102]. The etiologies for IUGR are numerous
and heterogeneous, but are often associated with abnor-
malities in placental structure and function. Trophoblast
invasion in IUGR pregnancies is largely restricted to the
decidual portion of the spiral arteries [102].
Missed abortion is yet another developmental disorder
associated with severe defects in placental growth, result-
ing in losses within the first two months of gestation.
These conceptuses often have poor villous development
with abnormal stromal cells and reduced vascular branch-
ing [103].
Inadequate trophoblast proliferation leads to premature
development of intermediate villi. This results in exten-
sive differentiation and untimely end of villous growth.
The resulting placenta is unusually small and despite its
highly differentiated villi, does not provide adequate sur-
face area for gaseous/nutrient exchange. Typical examples
comprise maturitas praecox placentae, hypermaturity, and
pregnancies complicated with IUGR with Doppler high
resistance index in the umbilical arteries [89,98].
Conclusions: the human placenta – a model to 
study regulation of cell growth/proliferation
One of the most important outcomes of intensive research
on placental biology, is the emergence of the human tro-
phoblast as an ideal model system to investigate a variety
of cellular processes. The normal human cytotrophoblast
expresses functional tumor-associated genes, which are
essential prerequisites for a malignant phenotype. The
study of the control of these genes in normal cells, or in
the physiological context, may therefore, reveal a basis for
the future treatment of cancer. These cells produce bothPage 9 of 12
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capable of providing themselves an auto-stimulatory
growth impetus. Therefore, molecular changes responsi-
ble for the overt phenotypic presentation of neoplasias are
highly amenable to study using these tumor-like cells.
Interestingly, the onset of terminal differentiation effec-
tively curbs their tumor-like properties. Thus while on one
hand, human placental cells are bestowed with a capacity
to proliferate indefinitely and invade extensively, on the
other, these cells are also replete with mechanisms to reg-
ulate these tumor-like attributes and eventually progress
to a senescent apoptotic state. Our studies provide evi-
dence for the existence of both these regulated cellular
processes during placental growth [36,90,104,105]. Stud-
ies also indicate that proteins such as hCG, that are abso-
lutely essential for the endocrine maintenance of
pregnancy, can also play critical roles in the induction of
terminal differentiation of trophoblast cells and thereby
check the proliferative potential of these otherwise tumor-
like cells [106]. The placenta therefore represents an
autonomous or a self-sufficient unit capable of modulat-
ing its own growth and function. In addition, abnormal
growth, differentiation, and neoplastic transformation of
placental cells may result in miscarriage and in the devel-
opment of gestational trophoblastic tumors, characterized
by an aberrant hormone profile. These unique features
qualify trophoblast cells as ideal models for studies on the
regulation of cell growth, differentiation as well as car-
cinogenesis.
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